Wirkstoffe & Arzneimittelsicherheit

Nebenwirkungen · Wezenla

WEZENLA 45 mg solution for injection WEZENLA 45 mg solution for injection in pre-filled syringe WEZENLA 90 mg solution for injection in pre-filled syringe · Abschnitt 4.8 · PDF-Seite 30

HOS-151632 · Präparat HOS-100575

Table 4 provides a list of adverse reactions from adult psoriasis, psoriatic arthritis, Crohn’s disease and ulcerative colitis clinical studies as well as adverse reactions reported from post-marketing experience. The adverse reactions are classified by system organ class and frequency, using the following convention: very common (≥ 1/10), common (≥ 1/100 to < 1/10), uncommon (≥ 1/1 000 to < 1/100), rare (≥ 1/10 000 to < 1/1 000), very rare (< 1/10 000), not known (cannot be estimated from the available data). Within each frequency grouping, adverse reactions are presented in order of decreasing seriousness.

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.